Manufacturing

Considering Blow-Fill-Seal for Biologic Drugs

The continuous, aseptic fill/finish process is finding use in vaccines and biologic drugs.

The Lighthouse Effect

Lighthouse manufacturing techniques utilize technology and automation to streamline production.

Qualifying AI Algorithms in Pharma Manufacturing

Qualified algorithms enable validation of machine learning models.

Vaxzevria Gains Approval in EU as a Third Dose COVID-19 Booster in Adults

May 24, 2022

AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.

FDA Stresses Risk Management Plans

May 20, 2022

The agency is asking drug manufacturers to ensure a strong supply chain by developing risk management plans.

Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity in US Facility

May 20, 2022

Catalent has announced a $175 million project to expand its manufacturing facility for large scale oral dose forms at its Winchester, Ky, site.

Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities

May 15, 2022

CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.

Converting Injectable Therapies to Combination Drug-Device Products

May 15, 2022

The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.

Avantor and Cytovance Biologics Partner on Plasmid DNA Development

May 13, 2022

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

PCI Pharma Services Invests $100 Million in Bedford, NH Manufacturing Facility

May 12, 2022

PCI Pharma Services is investing $100 million in manufacturing capabilities and capacity expansion to its Bedford, NH facility.

Shining a Spotlight on Nucleic Acid-Based Therapeutics

May 11, 2022

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Scaling Up Cell Therapies Capacity

May 11, 2022

Outsourcing partners are ready to fill the market need for greater cell therapies capacities.

MilliporeSigma’s ZooMAb Antibodies Earn ACT Label from My Green Lab

May 09, 2022

MilliporeSigma’s ZooMAb antibodies have been recognized for their low environmental impact by My Green Lab.